Appendiceal Cancer: Borrowing an Adjuvant Regimen From a Different Disease
No trial has ever tested an adjuvant regimen for this specific cancer — so the regimen on the table today is borrowed, not built, and the team has to decide how much that borrowing actually costs.
Y.M., a 51-year-old man, manages a small produce distribution warehouse and was rushed to emergency surgery six weeks ago for what looked, on the CT scan that night, like a straightforward case of acute appendicitis — until the pathology from his appendectomy came back showing a 2.5cm intestinal-type adenocarcinoma at the appendiceal base, prompting a formal right hemicolectomy two weeks later that found one of eighteen lymph nodes involved. Mismatch repair testing showed intact protein expression — microsatellite stable disease, unlike the meaningfully higher rate of MSI-H tumors seen in small bowel adenocarcinoma, a related but genuinely distinct entity his surgeon initially, and incorrectly, described to him as "basically the same thing as colon cancer."
Appendiceal adenocarcinoma is rare enough that no dedicated randomized adjuvant chemotherapy trial has ever been conducted for it — current practice extrapolates directly from colon cancer's own adjuvant evidence — chiefly MOSAIC (Andre et al., NEJM 2004), which established oxaliplatin's adjuvant benefit in resected stage III colon cancer — typically as FOLFOX or CAPOX, on the reasoning that both are intestinal-type adenocarcinomas arising from similar embryologic tissue with broadly overlapping histology. But appendiceal adenocarcinoma's molecular profile, natural history, and patterns of spread — particularly its tendency toward peritoneal dissemination even in early-stage disease — genuinely differ from colon cancer in ways that a borrowed regimen's efficacy has never actually been measured against. Y.M.'s node-positive, intestinal-type, microsatellite-stable tumor is close enough to typical colon cancer biology that the extrapolation feels reasonable to most of the team — but "feels reasonable" and "has been shown to work" are not the same claim, and the distinction is one Y.M. deserves to hear stated plainly before he commits to six months of treatment. One of eighteen nodes is the whole of his indication, and it is doing double duty: in colon cancer that finding carries a randomized adjuvant benefit, while here it is only the feature used to argue he resembles the patients in whom that benefit was demonstrated. The same node count is strong evidence in one disease and an analogy in his.
Post-operative oncology clinic, discussing adjuvant treatment
His tumor is intestinal-type, non-mucinous, node-positive, and microsatellite-stable — among appendiceal adenocarcinoma's genuinely varied subtypes, this is the one that looks most like the colon cancer biology adjuvant FOLFOX was actually developed for. I'd recommend it, on the basis that the extrapolation is more defensible here than a blanket "appendiceal cancer equals colon cancer" claim would be.
I don't disagree that the biological analogy is reasonable, but "more defensible than the alternative" is still an extrapolation, not a demonstrated result. No randomized trial has ever tested adjuvant chemotherapy specifically in resected appendiceal adenocarcinoma, of any subtype. Y.M. is about to sign up for six months of oxaliplatin-based toxicity — neuropathy, fatigue, GI effects — and I think he needs to hear, in plain terms, that the regimen's evidence base comes entirely from a different cancer, not a softened version of that fact.
This isn't an argument against treating him — it's an argument for exactly what we tell him while we do.
I'd add one more layer before we finalize anything: appendiceal adenocarcinoma covers real histologic diversity — mucinous, goblet-cell, intestinal-type — and they don't all behave the same way or presumably respond the same way to a borrowed regimen. A more detailed pathology review, including any additional immunohistochemical markers that might further characterize his specific subtype, could sharpen exactly how much weight the colon-cancer analogy should carry for him, rather than treating "appendiceal adenocarcinoma" as a single answer.
Agreed: adjuvant CAPOX for six months, with additional pathology review of Y.M.'s specific appendiceal subtype obtained in parallel, and a clear, explicit conversation with him disclosing that no randomized trial has directly tested this regimen in appendiceal adenocarcinoma — the recommendation rests on extrapolation from colon cancer, stated to him plainly rather than implied to carry the same evidence weight.
Not fully resolved: whether the additional pathology characterization, once available, might meaningfully change the regimen recommendation was left as an open, revisitable question rather than answered in advance — the team proceeded with treatment now rather than delaying adjuvant therapy for a result that was not expected to change the immediate decision.